- Home
- GDTC vs BIAF Comparison
GDTC vs BIAF Comparison
Compare GDTC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- BIAF
- Stock Information
- Founded
- GDTC 2018
- BIAF 2014
- Country
- GDTC Singapore
- BIAF United States
- Employees
- GDTC N/A
- BIAF N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GDTC Health Care
- BIAF Health Care
- Exchange
- GDTC Nasdaq
- BIAF Nasdaq
- Market Cap
- GDTC 25.1M
- BIAF 21.4M
- IPO Year
- GDTC 2023
- BIAF 2022
- Fundamental
- Price
- GDTC $2.17
- BIAF $1.31
- Analyst Decision
- GDTC Buy
- BIAF Strong Buy
- Analyst Count
- GDTC 1
- BIAF 1
- Target Price
- GDTC $5.00
- BIAF $6.00
- AVG Volume (30 Days)
- GDTC 22.4K
- BIAF 150.9K
- Earning Date
- GDTC 01-01-0001
- BIAF 11-14-2024
- Dividend Yield
- GDTC N/A
- BIAF N/A
- EPS Growth
- GDTC N/A
- BIAF N/A
- EPS
- GDTC N/A
- BIAF N/A
- Revenue
- GDTC $330,254.00
- BIAF $9,367,785.00
- Revenue This Year
- GDTC $14.71
- BIAF $302.41
- Revenue Next Year
- GDTC N/A
- BIAF $15.00
- P/E Ratio
- GDTC N/A
- BIAF N/A
- Revenue Growth
- GDTC N/A
- BIAF 2813.87
- 52 Week Low
- GDTC $1.20
- BIAF $1.21
- 52 Week High
- GDTC $5.50
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- GDTC 47.02
- BIAF 40.08
- Support Level
- GDTC $2.11
- BIAF $1.21
- Resistance Level
- GDTC $2.60
- BIAF $1.37
- Average True Range (ATR)
- GDTC 0.33
- BIAF 0.08
- MACD
- GDTC -0.07
- BIAF 0.01
- Stochastic Oscillator
- GDTC 34.42
- BIAF 45.45
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.